Wellness Program Improves Disease Markers & Physical Activity in Patients With MS
Data show statistically significant changes in 29-item MS Impact Scale and the Godin Leisure-Time Exercise Questionnaire scores with the MSAC wellness program
Stay updated with breaking news from Multiple Sclerosis Centers. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Data show statistically significant changes in 29-item MS Impact Scale and the Godin Leisure-Time Exercise Questionnaire scores with the MSAC wellness program
In a new study of more than 600 patients with multiple sclerosis, about 1 in 25 faced a potentially severe drug-drug interaction, with more having at least one potentially risky interaction.
The novel anti-CD20 monoclonal antibody ublituximab showed greater improvement vs terifulnomide in stabilizing disease progression in relapsing multiple sclerosis in two phase 3 trials.
The investigational evobrutinib, an Bruton's tyrosine kinase inhibitor, showed favorable safety and efficacy in the longest trial to date of a drug in this class in patients with multiple sclerosis.
Ofatumumab treatment was not associated with high rates of severe or breakthrough COVID-19 among patients with relapsing multiple sclerosis.